412-246-6111

 

ROCHE

RO4917523 Study

 

  

Home     Depression     Bipolar Disorder     Cognitive Therapy     Research     Staff     Contact    TV ADs
 

 

Current Studies

Depression:

* Insomnia & Depression

* Transcranial Magnetic Stimulation (TMS)

* New Medication Trial (ROCHE)

* Buprenorphine for TRD

* New Medication Trial (Shire)

Assessment Only:

* Emotion/Physiology

Bipolar Disorder:

* Quetiapine vs. Lithium

 

 

 

Purpose

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment
Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

 

 

 

For further information please call 412-246-6111, click here to email us, or visit clinicaltrials.gov. 

  
 

If you have any questions or comments about this web site, please contact the webmaster.  For all other questions please click the contact link.

This website was last updated 06/14/2012.

© 2005 Mood Disorders Treatment and Research Program (MDTRP), Department of Psychiatry, Western Psychiatric Institute and Clinic (WPIC), UPMC Health System